Oral Answers to Questions

Stephen Hepburn Excerpts

Wednesday 27th February 2019 Commons Chamber

[The Prime Minister]

I recognise that my right hon. Friend has been, and continues to be, a huge champion for social mobility. She is asking me to provide a solution to higher education funding and student finance before the Augar report has been received and published. All I can do is assure her that Philip Augar and his panel are working on the report and we will look seriously at the proposals they bring forward.

[Mr Stephen Hepburn (Jarrow) (Lab)]

Q12. In my constituency of Jarrow there is a wonderful young lady, four-year-old Harriet Corr, whose life would improve dramatically if she had access to the cystic fibrosis drug Orkambi. It is available in Ireland and many other European countries, and is due to become available in Scotland. Will the Prime Minister intervene personally in the negotiations between the NHS and Vertex to ensure that Harriet’s family and many other families are not forced to leave their homes and move elsewhere?

[The Prime Minister]

I am sure the whole House will recognise the concerns of Harriet and her family. We want to ensure that patients have access to the most effective and innovative medicines, but obviously at a price that represents value to the NHS. NHS England has proposed its best ever offer for a drug. This offer is the largest ever commitment of its kind in the 70-year history of the NHS, and would guarantee immediate and expanded access both to Orkambi and the drug Kalydeco for patients who need it. We have been closely following the discussions, and the Secretary of State for Health and Social Care has offered a meeting with the global chief executive officer of Vertex, NHS England and the National Institute for Health and Care Excellence in an effort to move the situation forward for the benefit of patients.